Comparative Pharmacology
Head-to-head clinical analysis: ACTIFED versus VASOCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIFED versus VASOCON A.
ACTIFED vs VASOCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
None Documented
None Documented
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (pH-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Category C
Category C
Decongestant/Antihistamine Combination
Ophthalmic Decongestant/Antihistamine Combination